Allergen immunotherapy as add-on to biologic agents

Carlo Lombardi, Giorgio W. Canonica, Giovanni Passalacqua

Research output: Contribution to journalArticle

Abstract

PURPOSE OF REVIEW: In this review, we sought to outline many of the recent evidences about the available clinical trials in which biologic agents [i.e. omalizumab (OMA)] were associated as add-on to allergen-specific immunotherapy (AIT).

RECENT FINDINGS: The available literature shows that OMA may be a valuable option as add-on to AIT for respiratory allergy, or food desensitization, especially in the escalation or build-up phases, in which adverse events are more commonly expected. The encouraging data for hymenoptera venom allergy remain limited to case reports, and no structured clinical trial is available.

SUMMARY: Over the past decade, studies of OMA used with AIT have shown promising results. Today, big randomized, double-blind, placebo-controlled trials are needed to better select those patients who would benefit from the addition of OMA (or other biologic agents) to AIT, as well as optimal dosing schedules, optimal duration of treatments and, finally, adequate evaluation about pharmacoeconomic aspects.

Original languageEnglish
Pages (from-to)502-508
Number of pages7
JournalCurrent Opinion in Allergy and Clinical Immunology
Volume18
Issue number6
DOIs
Publication statusPublished - Dec 1 2018

Fingerprint

Immunologic Desensitization
Biological Factors
Clinical Trials
Pharmaceutical Economics
Hymenoptera
Food Hypersensitivity
Venoms
Appointments and Schedules
Hypersensitivity
Placebos
Omalizumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Allergen immunotherapy as add-on to biologic agents. / Lombardi, Carlo; Canonica, Giorgio W.; Passalacqua, Giovanni.

In: Current Opinion in Allergy and Clinical Immunology, Vol. 18, No. 6, 01.12.2018, p. 502-508.

Research output: Contribution to journalArticle

Lombardi, Carlo ; Canonica, Giorgio W. ; Passalacqua, Giovanni. / Allergen immunotherapy as add-on to biologic agents. In: Current Opinion in Allergy and Clinical Immunology. 2018 ; Vol. 18, No. 6. pp. 502-508.
@article{146e668c792544aea17b586d6141b201,
title = "Allergen immunotherapy as add-on to biologic agents",
abstract = "PURPOSE OF REVIEW: In this review, we sought to outline many of the recent evidences about the available clinical trials in which biologic agents [i.e. omalizumab (OMA)] were associated as add-on to allergen-specific immunotherapy (AIT).RECENT FINDINGS: The available literature shows that OMA may be a valuable option as add-on to AIT for respiratory allergy, or food desensitization, especially in the escalation or build-up phases, in which adverse events are more commonly expected. The encouraging data for hymenoptera venom allergy remain limited to case reports, and no structured clinical trial is available.SUMMARY: Over the past decade, studies of OMA used with AIT have shown promising results. Today, big randomized, double-blind, placebo-controlled trials are needed to better select those patients who would benefit from the addition of OMA (or other biologic agents) to AIT, as well as optimal dosing schedules, optimal duration of treatments and, finally, adequate evaluation about pharmacoeconomic aspects.",
author = "Carlo Lombardi and Canonica, {Giorgio W.} and Giovanni Passalacqua",
year = "2018",
month = "12",
day = "1",
doi = "10.1097/ACI.0000000000000479",
language = "English",
volume = "18",
pages = "502--508",
journal = "Current Opinion in Allergy and Clinical Immunology",
issn = "1528-4050",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Allergen immunotherapy as add-on to biologic agents

AU - Lombardi, Carlo

AU - Canonica, Giorgio W.

AU - Passalacqua, Giovanni

PY - 2018/12/1

Y1 - 2018/12/1

N2 - PURPOSE OF REVIEW: In this review, we sought to outline many of the recent evidences about the available clinical trials in which biologic agents [i.e. omalizumab (OMA)] were associated as add-on to allergen-specific immunotherapy (AIT).RECENT FINDINGS: The available literature shows that OMA may be a valuable option as add-on to AIT for respiratory allergy, or food desensitization, especially in the escalation or build-up phases, in which adverse events are more commonly expected. The encouraging data for hymenoptera venom allergy remain limited to case reports, and no structured clinical trial is available.SUMMARY: Over the past decade, studies of OMA used with AIT have shown promising results. Today, big randomized, double-blind, placebo-controlled trials are needed to better select those patients who would benefit from the addition of OMA (or other biologic agents) to AIT, as well as optimal dosing schedules, optimal duration of treatments and, finally, adequate evaluation about pharmacoeconomic aspects.

AB - PURPOSE OF REVIEW: In this review, we sought to outline many of the recent evidences about the available clinical trials in which biologic agents [i.e. omalizumab (OMA)] were associated as add-on to allergen-specific immunotherapy (AIT).RECENT FINDINGS: The available literature shows that OMA may be a valuable option as add-on to AIT for respiratory allergy, or food desensitization, especially in the escalation or build-up phases, in which adverse events are more commonly expected. The encouraging data for hymenoptera venom allergy remain limited to case reports, and no structured clinical trial is available.SUMMARY: Over the past decade, studies of OMA used with AIT have shown promising results. Today, big randomized, double-blind, placebo-controlled trials are needed to better select those patients who would benefit from the addition of OMA (or other biologic agents) to AIT, as well as optimal dosing schedules, optimal duration of treatments and, finally, adequate evaluation about pharmacoeconomic aspects.

UR - http://www.scopus.com/inward/record.url?scp=85055910333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055910333&partnerID=8YFLogxK

U2 - 10.1097/ACI.0000000000000479

DO - 10.1097/ACI.0000000000000479

M3 - Article

C2 - 30148718

AN - SCOPUS:85055910333

VL - 18

SP - 502

EP - 508

JO - Current Opinion in Allergy and Clinical Immunology

JF - Current Opinion in Allergy and Clinical Immunology

SN - 1528-4050

IS - 6

ER -